Navigation Links
Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
Date:10/29/2013

ALISO VIEJO, Calif., Oct. 29, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary financial information (unaudited) for the year ended September 30, 2013, in anticipation of the company's Investor Relations Day in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Based on preliminary financial information for the fiscal year-ended September 30, 2013, Avanir estimates:

  • Total gross revenues of approximately $95.9 million (Non-GAAP)
  • Total net revenues in the range of approximately $75.3 million to $76.3 million
  • Total operating expenses of approximately $116.0 million, excluding cost of product sales of approximately $4.0 million, non-cash items such as share-based compensation of approximately $5.8 million, and depreciation and amortization of long-lived assets of approximately $800,000 and the one-time upfront payment to OptiNose of $20.0 million (Non-GAAP)
  • Cash, cash equivalents and investments in securities totaling approximately $57.5 million, including cash and cash equivalents of approximately $55.3 million and restricted investments in securities of approximately $2.2 million

"We are delighted with the progress of our NUEDEXTA PBA commercial business this year," said Keith Katkin, president and CEO of Avanir. "In addition, the R&D team has made great progress with our pipeline. We now have three active phase II studies of AVP-923 including MS neuropathic pain, Alzheimer's agitation, and the recently announced levodopa-induced dyskinesias in Parkinson's disease.  We continue to expect top-line data from our PRIME study in MS neuropathic pain
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
2. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
3. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
4. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
7. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
8. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
9. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
10. Avanir Pharmaceuticals to Participate in Two Conferences in August
11. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... YORK, Jan. 16, 2012 Reportlinker.com announces ... available in its catalogue: , ... http://www.reportlinker.com/p0751763/Global-Diagnostic-Imaging-Market-Trends-and-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ... imaging market, including: , Estimates ...
... 13, 2012  MedAssurant, Inc., a leading provider of ... for Quality Assurance (NCQA) Software Certification of its ... Data and Information Set (HEDIS®) measurement and reporting ... use, QSI is the nation,s most widely used ...
Cached Medicine Technology:Global Diagnostic Imaging Market Trends and Outlook 2MedAssurant Earns 2012 NCQA Software Certification 2
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
Breaking Medicine News(10 mins):Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... FRIDAY, July 29 (HealthDay News) -- The brains of ... signs of a brain disease associated with concussions, say ... findings revealed that Bobby Kuntz (of the Toronto Argonauts ... Rough Riders) had chronic traumatic encephalopathy (CTE). Both players ...
... is available in Spanish . Patients suffering ... attacked and pursued, with the particularity that they express them ... Neurology has published the third consecutive work in five ... The first work showed in 2006 that 45% ...
... FRIDAY, July 29 (HealthDay News) -- Developed countries have ... recent years, but a new international study suggests this ... about the availability of increasingly effective treatments and improving ... of World Health Organization (WHO) breast cancer data collected ...
... University of Cincinnati (UC) research on HIV testing at local ... who do not know they are infected with HIV, even ... study is part of a special supplement to the July ... the Centers for Disease Control and Prevention (CDC). The supplement ...
... Neuroscientists at the University of Bristol have received a ... Council (MRC) to continue their research into the pathological ... dementia, affecting around 465,000 people in the UK. ... latest research into how aspects of electrical signalling go ...
... WASHINGTON The U.S. Food and Drug Administration should gather ... replace the 35-year-old 510(k) clearance process for medical devices, says ... 510(k) process lacks the legal basis to be a reliable ... II devices and cannot be transformed into one, concluded the ...
Cached Medicine News:Health News:Concussion Project Finds Disease in Two Autopsied Brains 2Health News:REM sleep behavior disorder is a risk factor for Parkinson's disease 2Health News:Drop in Breast Cancer Death Rates May Not Be Linked to Screening Rates 2Health News:Drop in Breast Cancer Death Rates May Not Be Linked to Screening Rates 3Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
A rigid version of the popular flexible laparoscopic transducer. It has been proven that a rigid "lap transducer has great utility in the OR for being an extra lifting tool inside the abdomen....
This is a 3D transducer for endovaginal imaging in OB/GYN....
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer....
Medicine Products: